8-K: PepGen Reprices Underwater Options to Boost Retention

PepGen Inc. has repriced approximately two-thirds of its employee stock options to $4.53 per share, aiming to retain and motivate key personnel through a critical company stage.

Summary

• PepGen Inc. approved an option repricing, effective November 4, 2025, for options granted under its 2020, 2022, and 2024 Stock Plans.
• The repricing applies to options held by current employees, including executive officers James McArthur (CEO), Noel Donnelly (CFO), and Paul Streck (EVP, Head of R&D), that had an exercise price exceeding the 52-week high fair market value per share on November 4, 2025.
• The new exercise price for these eligible options is $4.53 per share.
• To exercise the repriced options at the reduced price, participants must remain in service with the Company through a Retention Period, which ends on the earliest of March 31, 2027, or a Sale/Sale Event of the Company.
• Approximately two-thirds of outstanding stock options held by Company employees were underwater, with previous exercise prices ranging from $8.89 to $17.91 per share, covering a total of 3,557,903 shares.

Sentiment

Score: 4

Explanation: While the repricing is a proactive measure to address a negative situation (underwater options) and aims to improve employee retention and motivation, the underlying reason for the repricing—a significant decline in stock price leading to two-thirds of options being underwater—is a strong negative indicator of past performance and market perception. The action itself is positive for talent retention but stems from a negative financial reality.

Positives

• The repricing is designed to retain and motivate key employees, including executive officers, through what the company describes as a critical stage.
• It addresses the issue of underwater stock options, which can significantly demotivate employees and lead to talent attrition.
• The Board followed robust corporate governance procedures, with an interested director recusing himself and disinterested directors approving the repricing based on recommendations from the Compensation Committee and advice from independent compensation consultants and legal counsel.

Negatives

• Approximately two-thirds of outstanding employee stock options were underwater, indicating a significant decline in the company's stock price from previous highs.
• The necessity of repricing suggests past poor stock performance, which could reflect negatively on investor confidence and prior management strategies.
• The repricing effectively lowers the hurdle for employees to gain value from their options, which could be viewed as dilutive or a concession to employees at the expense of shareholders if not justified by future performance.

Risks

• Risk of employee demotivation and potential departure if the issue of underwater options had not been addressed.
• Potential for shareholder dissatisfaction if the repricing is perceived as overly generous or not sufficiently tied to future performance improvements.
• The company is navigating a 'critical stage,' implying inherent business risks that necessitate strong employee retention to overcome.

Future Outlook

The option repricing is explicitly designed to retain and motivate eligible participants to continue working in the best interests of the Company and its stockholders through a 'critical stage' for the Company, indicating an expectation of significant future challenges or milestones that require stable and motivated leadership.

Management Comments

• "The Repricing, including the provision of the Retention Period, was designed with the objectives of retaining and motivating the Eligible Participants to continue to work in the best interests of the Company and its stockholders through a critical stage for the Company."

Industry Context

Option repricing is a common strategy in the biotechnology and pharmaceutical sectors, particularly for growth-stage companies whose stock prices can experience significant volatility due to factors like clinical trial results, regulatory approvals, or broader market sentiment. When stock options become underwater, they lose their incentive value, prompting companies to reprice them to retain crucial scientific and executive talent, which is vital for long-term success in R&D-intensive industries.

Comparison to Industry Standards

• Option repricing is a recognized, though sometimes debated, practice in industries like biotech where stock performance can be highly volatile. Companies such as Sarepta Therapeutics and Editas Medicine have undertaken similar repricing initiatives following significant stock declines to maintain employee morale and prevent talent drain.
• The inclusion of a 'Retention Period' (until March 31, 2027, or a Sale Event) is a common safeguard to ensure continued service and align employee incentives with long-term company performance, mirroring practices seen at other growth-oriented companies during market downturns.
• The recusal of an interested director (Dr. McArthur) and approval by disinterested directors, with advice from independent consultants and legal counsel, aligns with best practices in corporate governance for such transactions, comparable to the rigorous review processes at established pharmaceutical firms.

Corporate Governance

Related Party Transactions

• Dr. James McArthur, the Company's Chief Executive Officer and principal executive officer, recused himself from the Board vote on the approval of the Repricing due to his status as an interested director, as defined by Section 144 of the Delaware General Corporation Law.

Stakeholder Impact

• Shareholders: Potential for increased dilution from repriced options, but also benefits from retained key talent and improved employee motivation, which could lead to better long-term company performance and stability.
• Employees (Eligible Participants): Significant positive impact as their underwater stock options regain incentive value, enhancing motivation, retention, and potential future compensation.
• Executive Officers: Directly benefit from the repricing, aligning their incentives more closely with the company's future success and providing a renewed financial incentive.

Next Steps

• Eligible Participants must remain in service through the Retention Period (until March 31, 2027, or a Sale/Sale Event) to exercise repriced options at the reduced price.
• The company will continue to operate through a 'critical stage' where employee retention is deemed vital for its future success.

Key Dates

Recommendation

The repricing of underwater options indicates past poor stock performance, which is a negative signal. However, this proactive measure to retain key talent, especially through a 'critical stage,' is a necessary step to stabilize the company and potentially drive future value. This action, while addressing a negative, does not fundamentally alter the company's underlying business prospects in the short term but mitigates a significant risk (talent drain). Therefore, a 'hold' recommendation is appropriate, awaiting further clarity on the company's performance through its critical stage and the impact of this retention strategy.

Keywords

PepGen, stock options, option repricing, employee retention, executive compensation, corporate governance, underwater options, biotechnology, pharmaceuticals, Nasdaq